NASDAQ:GENB

Generate Biomedicines (GENB) Stock Price, News & Analysis

Generate Biomedicines logo
$9.54 -0.83 (-8.00%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$9.73 +0.19 (+1.97%)
As of 11/20/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Generate Biomedicines Stock (NASDAQ:GENB)

Advanced

Key Stats

Today's Range
$9.40
▼
$10.58
50-Day Range
$9.54
▼
$17.46
52-Week Range
$9.40
▼
$22.67
Volume
967,205 shs
Average Volume
957,995 shs
Market Capitalization
$1.23 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.20
Consensus Rating
Moderate Buy

Company Overview

Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts.

Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.

Generate Biomedicines is led by Chief Executive Officer Mike Nally. The company’s research and development activities are based in the United States, while its medicines are intended for patients in markets where they may ultimately receive regulatory approval.

AI Generated. May Contain Errors.

Generate Biomedicines Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

GENB MarketRank™: 
2.005842259005 of 5 stars

Generate Biomedicines scored higher than 40% of companies evaluated by MarketBeat, and ranked 610th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Generate Biomedicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Generate Biomedicines has a consensus price target of $26.20, representing about 174.6% upside from its current price of $9.54.

  • Amount of Analyst Coverage

    Generate Biomedicines has only been the subject of 3 research reports in the past 90 days.

  • Read more about Generate Biomedicines' stock forecast and price target.
  • Earnings Growth

    Earnings for Generate Biomedicines are expected to grow in the coming year, from ($2.60) to ($2.44) per share.

  • Price to Book Value per Share Ratio

    Generate Biomedicines has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.08% of the float of Generate Biomedicines has been sold short.
  • Short Interest Ratio / Days to Cover

    Generate Biomedicines has a short interest ratio ("days to cover") of 8.87.
  • Change versus previous month

    Short interest in Generate Biomedicines has recently increased by 1.73%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Generate Biomedicines does not currently pay a dividend.

  • Dividend Growth

    Generate Biomedicines does not have a long track record of dividend growth.

  • News Sentiment

    Generate Biomedicines has a news sentiment score of -0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Generate Biomedicines this week, compared to 2 articles on an average week.
  • Search Interest

    Only 2 people have searched for GENB on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Generate Biomedicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
Receive GENB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Generate Biomedicines and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GENB Stock News Headlines

HC Wainwright Issues Pessimistic Estimate for GENB Earnings
A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
Generate Biomedicines: Q3 earnings snapshot
See More Headlines

GENB Stock Analysis - Frequently Asked Questions

Generate Biomedicines' stock was trading at $12.21 on March 10, 2026. Since then, GENB stock has decreased by 21.9% and is now trading at $9.54.

Generate Biomedicines Inc (NASDAQ:GENB) posted its quarterly earnings results on Thursday, November, 12th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.18. The firm earned $4.22 million during the quarter. Generate Biomedicines had a negative net margin of 1,289.97% and a negative trailing twelve-month return on equity of 151.21%.

Generate Biomedicines (GENB) raised $400 million in an initial public offering (IPO) on Friday, February 27th 2026. The company issued 25,000,000 shares at a price of $15.00-$17.00 per share.

Generate Biomedicines' top institutional shareholders include Banque Pictet & Cie SA (1.38%), State Street Corp (0.43%), Alps Advisors Inc. (0.13%) and Goldman Sachs Group Inc. (0.11%).

Shares of GENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/12/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:GENB
CIK
2100782
Fax
N/A
Employees
312
Year Founded
2018

Price Target and Rating

High Price Target
$30.00
Low Price Target
$21.00
Potential Upside/Downside
+174.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.27)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$203.15 million
Net Margins
-1,289.97%
Pretax Margin
-1,321.10%
Return on Equity
-151.21%
Return on Assets
-54.73%

Debt

Debt-to-Equity Ratio
0.02
Current Ratio
5.01
Quick Ratio
5.01

Sales & Book Value

Annual Sales
$31.89 million
Price / Sales
38.62
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.95 per share
Price / Book
3.23

Miscellaneous

Outstanding Shares
129,100,000
Free Float
N/A
Market Cap
$1.23 billion
Optionable
Optionable
Beta
N/A

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:GENB) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners